387 related articles for article (PubMed ID: 33046037)
21. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
22. Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia.
Jia L; Yang H; Zheng D; Ye J; Zhou Q; Li G; Zhou Y; Yang X; Liu J; Ye F; Song Y; Ma D; Ji C
ACS Appl Mater Interfaces; 2023 Jun; 15(23):27624-27637. PubMed ID: 37249260
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
24. A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
He F; Sapkota S; Parker S; Defor T; Warlick E; Ustun C; Eckfeldt C; Rashidi A; Kurtzweil A; Weisdorf D; Bejanyan N
Leuk Lymphoma; 2018 Oct; 59(10):2352-2359. PubMed ID: 29415603
[TBL] [Abstract][Full Text] [Related]
25. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
26. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Karagiannis P; Alsdorf W; Tallarek AC; Blohm ME; Oelrich J; Waizenegger JS; Wolschke C; Hecher K; Singer D; Bokemeyer C; Fiedler W
Br J Haematol; 2021 Jan; 192(2):e60-e63. PubMed ID: 33222152
[No Abstract] [Full Text] [Related]
27. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
28. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Ball BJ; Koller PB; Pullarkat V
Curr Opin Oncol; 2022 Sep; 34(5):531-539. PubMed ID: 35855507
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
32. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Pollyea DA; Jordan CT
Curr Opin Hematol; 2019 Mar; 26(2):71-76. PubMed ID: 30652974
[TBL] [Abstract][Full Text] [Related]
33. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L; Daver N
Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
35. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
36. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
37. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
38. BCL-2 inhibition in AML: an unexpected bonus?
Konopleva M; Letai A
Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
[TBL] [Abstract][Full Text] [Related]
39. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
40. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
